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ABSTRACT _
This paper discusses lipid therapy decision-making at the
population level within the United States (US) Military
Health Services System. The US Military Health Services
System serves approximately 8.2 million beneficiaries
fairly representative of the general population. Of its
$680 million annual pharmacy expenditure, $45-$50
million is spent on lipid-lowering drugs. The military
Medical Treatment Facilities (MTF) carry a Tri-Service
Drug Formulary list, which servesas a bare minimum to
which individual facilities may add other agents. The De-
partment of Defense Pharmacoeconomic Center (PEC)
performs cost-effectiveness analyses, establishes the Tri-
Service Drug Formulary list and the National Mail Order
Pharmacy formulary list, and provides drug treatment
T his paper discusses lipid therapy decision-making at the population level in the United
States (US) Military Health Services System. A
number of new proposals are currently being con-
sidered by the Assistant Secretary of Defense for
Health Affairs, which may change our current ap-
proach to formulary management. A description of
the general approach to formulary management of
the US Military Health Services System is reported
in this paper. Past and potential future formulary
decisions regarding lipid-lowering therapies are dis-
cussed as well.
The US Military Health Services System
The beneficiary population of the US Military
Health Services System encompasses 1.6 million ac-
tive duty individuals and approximately 6.6 million
nonactive duty family members, retirees, and retiree
family members. While the active duty segment in-
cludes mainly young, fit, and healthy individuals,
the entire system population is thought to be demo-
graphically representative of the general US popula-
tion. Within this beneficiary population, patients
who receive lipid-lowering drugs average 60 years
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guidelines. Hyperlipidemia treatment guidelines pub-
lished by the Pharmacoeconomic Center in 1995, which
recommend the use of niacin, colestipol, and pravastatin,
are currently under revision to take into consideration
new drugs and new information in the fieldof lipid-lower-
ing therapies. Future changes to the MTF outpatient for-
mulary management may include the introduction of a
Basic Core List of essential agents and a Master Pharma-
ceutical Agent List comprising the only drugs from which
facilities may choose to add to their Basic Core List.
These changes are designedto standardize drug availabil-
ity across military facilities and to leverage market share
for lower drug prices.
in age. The Military Health Services System has two
major components.
1. Military Medical Treatment Facilities (MTFs)
constitute the direct care system. Approximately
600 military hospitals and clinics located around
the world provide almost all of the active duty
care.
2. Under the regionally managed TRICARE pro-
gram, contracts are established with civilian man-
aged care firms to supplement the capacity of the
direct care system. Nonactive duty beneficiaries
choose from three TRICARE options that differ
in copayment schemes and limitations on pro-
vider choice. TRICARE will replace the existing
indemnity health insurance program known as
the Civilian Health and Medical Program of the
Uniformed Services (CHAMPUS).
As the downsizing of the US military reduces
the size of the direct care system, the contracted
managed care component will likely accommodate
a growing number of patients.
Military system patients may obtain medications
from a number of sources including military MTF
pharmacies, TRICARE contractor network phar-
macies, and a recently instituted Department of De-
fense National Mail Order Pharmacy (NMOP)
(Fig. 1). The military MTF pharmacies fill approxi-
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Figure I The US Military Health Services System and drug formulary management.
mately 40 million prescriptions annually at a cost of
$680 million. Of this, $45-50 million is spent on
lipid-lowering drugs, which constitute one of the
largest single drug class expenditures. Total annual
drug expenditures in the TRICARFlCHAMPUS
program amount to $200 million.
The Department of Defense
Pharmacoeconomic Center
The Department of Defense Pharmacoeconomic
Center (PEC) performs pharmacoeconomic stud-
ies that are used to manage the Tri-Service Formu-
lary (TSF). The TSF currently lists 130 drugs that
all military MTFs must have on their formularies.
While this list serves as the minimum requirement,
individual facilities typically add other agents to
their formulary. The PEC also establishes treat-
ment guidelines to be considered and adopted by
each military medical treatment facility.
The Pharmacoeconomic Center modeled the cost-
effectiveness of lipid-lowering drugs in order to se-
lect agents for the TSF and develop a hyperlipidemia
treatment guideline in October 1995 [1]. The cor-
onary heart disease (CHD) risk categories and the
low density lipoprotein cholesterol (LDL-C) treat-
ment goals outlined in the second report of the
National Cholesterol Education Program (NCEP)
Adult Treatment Panel [2] formed the basis for the
cost-effectiveness model. The PEC operationally
defined the effectiveness of a drug as the percent-
age of patients who would be predicted to achieve
their LDL-C treatment goals with that drug. Data
from clinical trials, compliance studies, and the Na-
tional Health and Nutritional Examination Survey
III (NHANES III) were used to estimate the effec-
tiveness of each drug. Direct medical costs were es-
timated from the perspective of the government as
the payer. The costs of drug acquisition, provider
visits, and laboratory tests were included in the
analysis. Based on cost-effectiveness analyses, three
drugs were selected for the TSF in October 1995:
1. colestipol: agent of choice for primary prevention;
2. pravastatin: agent of choice for secondary pre-
vention;
3. niacin: inexpensive alternative for patients who
can tolerate it.
Even though colestipol, a bile-acid sequestrant,
does not reduce LDL-C as much as statins, it was
the most cost-effective agent for primary preven-
tion. The smaller percentage reductions in LDL-C
that are required for primary prevention allowed
colestipol to achieve a predicted level of effective-
ness that, when coupled with a low acquisition cost,
yielded the smallest cost-effectiveness ratio. Pravas-
tatin was the most cost-effective agent for secondary
prevention because it was the least expensive agent
that lowered LDL-C sufficiently to reach the more
stringent treatment goals for patients with existing
CHD. The effectiveness of niacin is limited by a rel-
atively high incidence of adverse effects, but it was
selected for the TSF because it is a very cost-effective
agent for patients who are able to tolerate it.
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Revision of Current Hyperlipidemia
Treatment Guidelines
In the near future, hyperlipidemia treatment guide-
lines used by military facility prescribers stand to be
revised for the following reasons.
1. Since 1995 new lipid-lowering drugs have been
made available. Their addition to the formu-
lary should be considered.
2. A substantial body of new information has been
accumulated on lipid-lowering therapies. For ex-
ample, new clinical evidence supports a greater
emphasis on secondary prevention and on more
aggressive treatment of diabetic patients.
3. The Pharmacoeconomic Center is involved in de-
veloping a formulary list for the recently estab-
lished National Mail Order Pharmacy (NMOP).
Although all statins are currently listed on the
NMOP formulary, lower prices might be ob-
tained by shifting market share to a subset of the
available agents.
4. The MTF outpatient formulary management is
currently in transition. A new concept not yet
officially approved is under development that
would include a Basic Core List (BCL) and a
Master Pharmaceutical Agent List (MPAL).
The BCL and MPAL will be designed to in-
crease the uniformity in the availability of medica-
tions at MTFs and to leverage market share for
lower drug prices. The BCL would be essentially
the same as the TSF-a list of drugs that all mili-
tary facilities must have on their formulary-but
would include more drugs than the previous TSF.
The major proposed change to the military for-
mulary system is the introduction of the MPAL.
This list will define the universe of medications
from which facilities may construct their formular-
ies. In the past, an individual MTF could add any
FDA-approved drug to its formulary. In the future,
if a drug is not listed on the MPAL, MTFs will no
longer be allowed to include that drug on their for-
mularies. If the MPAL includes only a subset of the
drugs available in a particular drug class, the mili-
tary should be able to leverage the shift in market
share for lower drug prices. This scheme will also
promote standardization among medical treatment
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facilities to the benefit of a mobile patient popula-
tion. If the MPAL includes only the statins listed on
the BCL, patients can be assured that the same
statins will be available at all facilities in the Mili-
tary Health Services System.
Conclusion
The Department of Defense Pharmacoeconomic
Center is currently completing pharmacoeconomic
analyses on lipid-lowering drugs. Results of these
analyses and published information in the field of
lipid-lowering therapies will be taken into consider-
ation to select the mix of drugs for the NMOP for-
mulary, the BCL, and the MPAL that will meet the
clinical needs of patients in a cost-effective manner.
Addendum
The proposed BCL and MPAL were not adopted.
Instead, the Acting Assistant Secretary of Defense
for Health Affairs established the Basic Core For-
mulary (BCF) in April 1998. The BCF is the same
as the Tri-Service Formulary, except that it will
contain some "closed" drug classes. If a drug class
is "closed" on the BCF, the drugs listed on the BCF
are the only drugs that MTFs are allowed to have
on their formularies within that drug class. The sta-
tin drug class will be closed.
The views expressed in this manuscript are those of the
authors and do not necessarily reflect the official policy
or position of the Department of the Army or the Depart-
ment of Defense of the US government. This article was
prepared with the assistance of BioMedCom Consultants
inc.,Montreal,Canada.
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